Pancreatic Adenocarcinoma

《 PANC-1 》

Work Up



* Note:
If tissue proved, optional testing for BRCA ½、MMR、NTRK

《PANC-2》

Work Up



《 PANC-3, -4, -5》

- **RESECTABLE**
- **BORDERLINE RESECTABLE NO METASTASES, PLANNED NEOADJUVANT THERAPY**
- **BORDERLINE RESECTABLE NO METASTASES, PLANNED RESECTION.**



《PANC-6》

POST-OP ADJUVANT TREATMENT



《 PANC-7》

LOCALLY ADVANCED UNRESECTABLE



《PANC-8》

METASTATIC DISEASE



《 PANC-9》

RECURRENCE AFTER RESECTION



《References》

1. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma Version 2.2025.
2. Mornex F,Girard N,Delpero J-R, Partensky C.Radiochemotherapy in the management of pancreatic cancer –part I:neoadjuvant treatment.Semin Radiat Oncol 2005;15:226-234
3. Bickenbach KA,Gonen M,Tang LH,et al.Downstaging in pancreatic cancer:a matched analysis of patients resected following treatment of initially locally unresectable disease .Ann Surg Oncol 2012;19:1663-1669.
4. Mondo EL,Noel MS,Katz w,ET AL.unresectable locally advanced pancreatic cancer:treatment with neoadjuvant leucovorin,fluo rouracil,irinotecan,and oxaliplatin and assessment of surgical resectability.J Clin Oncol 2013;31:e37- 39.
5. Tempero MA, Berlin J,Ducreux M,et al pancreatic cancer treatment and research:an international expert panel disscussion .Ann Oncol 2011;22:1500-1506.
6. Seiwert TY,Salama TY,Salama JK,Vokes EE.The concurrent chemoradiation paradigm—genearl principles.Nat Clin Pract Oncol 2007;4:86-100.
7. Girard N,Mornex F,Bossard N,et al estimating optimal dose of twice –weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma:mature results of GEMRT-01phase I trial.Int J Radiat Oncol Biol Phys 2010;77:1426-1432.
8. Murphy JD,Adusumilli S, Griffith KA,et al Full-dose gemcitabine and concurrent radiotherapy for unresectablepancreatic cancer.Int J Radiat Oncol Biol Phys 2007;68:801-808
9. Ammori JB,Colletti LM,Zalupski MM,er al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas.J Gastrointest Surg 2003;7:766-772.
10. Marti JL,Hochster HS,Hiotis SP,et al.PhaseI/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advancced pancreatic cancer.Ann Surg Oncol 2008;15:3521-3531.
11. Van Buren G,2nd,Ramanathan RK,Krasinskas AM, et al.Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2013;20:3787-3793

【胰臟癌放射治療共識】

一、**Target Volume**

1. pancreatic tumor and adjacent lymphatic chains

二、**Dose / Fraction**

CCRT: 45-56Gy, 1.8-2.2/Fx
SBRT: 30-50Gy in 3-5 Fx

三、**Treatment :**

3D-conformal radiation therapy or Intensity-modulated radiation therapy(IMRT) are used. Image-guided radiotherapy(IGRT) may be used in clinical settings. Treatment options including Simultaneous integrated boost(SIB) technique.

四、**References :**

1. NCCN clinical practice guidelines in oncology-pancreatic cancer. version 2.2025.
2. QUANTEC